How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Infectious Disease Archives

Early Release – Serologic Assessment of Public Health Action Needed for Trachoma, Coastal Ecuador, 2021–2024 – Volume 32, Number 11—November 2026 – Emerging Infectious Diseases journal

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected

October 3, 2026 No Comments

Early Release – Pediatric Deaths during Measles Outbreak, Jerusalem, Israel, 2025–2026 – Volume 32, Number 11—November 2026 – Emerging Infectious Diseases journal

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected

October 1, 2026 No Comments

Early Release – Serologic Assessment of Public Health Action Needed for Trachoma, Coastal Ecuador, 2021–2024 – Volume 32, Number 11—November 2026 – Emerging Infectious Diseases journal

Midterms Have Revived Universal Healthcare Debate. These States Are Ahead of Everyone.

Deadly MV Hondius Hantavirus Outbreak Is Over, W.H.O. Says

Four measles deaths, a looming policy comment deadline, and how to read a study: The State of US Vaccine Policy

Communicable disease threats report, 26 September

New hepatitis surveillance report shows strengthened public health cooperation with EU candidate countries

Risk to general population remains very low following fourth imported Ebola case in Europe

Hantavirus quarantine ends for Americans held for six weeks in Nebraska | US healthcare

Sepsis rates much higher for Black moms in Mississippi, analysis finds

Early Release – Pediatric Deaths during Measles Outbreak, Jerusalem, Israel, 2025–2026 – Volume 32, Number 11—November 2026 – Emerging Infectious Diseases journal

Schedule an Appointment

Quick Links

Patient Forms

Contact Us